CHMP2A anticorps (AA 1-222) (FITC)

N° du produit ABIN7147521

Détail du produit anti-CHMP2A anticorps (FITC)

Antigène: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Épitope: AA 1-222

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CHMP2A est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Charged multivesicular body protein 2a protein (1-222AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur CHMP2A

Antigène: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Autre désignation: CHMP2A (CHMP2A Produits)

Synonymes: anticorps BC-2, anticorps BC2, anticorps CHMP2, anticorps VPS2, anticorps VPS2A, anticorps 1500016L11Rik, anticorps RGD1305050, anticorps bc-2, anticorps bc2, anticorps chmp2, anticorps vps2, anticorps vps2a, anticorps fj10d05, anticorps wu:fi18h03, anticorps wu:fj10d05, anticorps zgc:55361, anticorps charged multivesicular body protein 2a, anticorps charged multivesicular body protein 2A, anticorps Charged multivesicular body protein 2a, anticorps charged multivesicular body protein 2A L homeolog, anticorps ATEG_06167, anticorps LOC5570080, anticorps EDI_289610, anticorps PTRG_09933, anticorps NAEGRDRAFT_39042, anticorps PITG_17335, anticorps Tsp_00033, anticorps LOC100284170, anticorps LOC100284688, anticorps chm2a, anticorps chmp2a, anticorps CHMP2A, anticorps Chmp2a, anticorps chmp2a.L

Sujet:

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis (PubMed:21310966). Together with SPAST, the ESCRT-III complex promotes nuclear envelope sealing and mitotic spindle disassembly during late anaphase (PubMed:26040712). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4.

Aliases: BC 2 antibody, BC2 antibody, Charged multivesicular body protein 2a antibody, CHM2A_HUMAN antibody, CHMP2 antibody, CHMP2a antibody, Chromatin modifying protein 2a antibody, Chromatin-modifying protein 2a antibody, hVps2 1 antibody, hVps2-1 antibody, putative breast adenocarcinoma marker antibody, Putative breast adenocarcinoma marker BC-2 antibody, Putative breast adenocarcinoma marker BC2 antibody, Vacuolar protein sorting associated protein 2 1 antibody, Vacuolar protein sorting-associated protein 2-1 antibody, Vps2 1 antibody, VPS2 antibody, Vps2-1 antibody, VPS2A antibody

UniProt: O43633

Pathways: SARS-CoV-2 Protein Interactome